
UCB
UCBJY | OTC
$161.62
-$2.13 (-1.30%)
At close: Nov 16, 2026, 3:59 PM ET
$161.62
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 3:59 PM ET
UCB Company Profile
Company profile explainedCompany Profile
UCB S.A. is a biopharmaceutical enterprise dedicated to developing innovative treatments and solutions for individuals living with neurological and immunological diseases. Its primary product, Cimzia, addresses a spectrum of inflammatory TNF-mediated conditions, encompassing ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. For epilepsy management, the company provides Vimpat, Keppra, and Briviact, alongside Nayzilam, an emergency nasal spray for seizure clusters. Neupro is offered for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal alleviate allergy symptoms. The portfolio further extends to Evenity, a treatment for osteoporosis in postmenopausal women, and BIMZELX, used for psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Dapirolizumab pegol is also available for systemic lupus erythematosus. UCB maintains a robust development pipeline featuring therapies such as rozanolixizumab for myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for stereotypic prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Additionally, the company engages in contract manufacturing services. UCB S.A. has forged collaborative agreements with partners including Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. Its operational presence spans the United States, Japan, Germany, a broader European footprint (including Spain, France, Italy, the United Kingdom, and Ireland), China, Belgium, and other global territories. Incorporated in 1925, the company's headquarters are situated in Brussels, Belgium.
Key Executives
| Name | Position |
|---|---|
| Jean-Christophe Tellier | Chief Executive Officer & Executive Director |
| Alistair Henry | Executive Vice President & Chief Scientific Officer |
| Caroline Vancoillie | Chief Accounting Officer & Head of Group Finance |
| Denelle J. Waynick Johnson | Executive Vice President & General Counsel |
| Emmanuel Caeymaex | Executive VP & Head of Patient Evidence |
| Fiona Du Monceau | Executive VP of Patient Impact & Chief Commercial Officer |
| Gwendoline Ornigg | Head of Global Corporate Communication |
| Jean-Luc Fleurial | Executive Vice President & Chief Human Resources Officer |
| Raf Remijsen | Head of Treasury & Risk Management |
| Sandrine Dufour | Executive VP & CFO |
| Veronique Toully | Head of Sustainability, Corporate Affairs & Enterprise Risk Management |
| Xavier Michel | VP & Group Secretary General |
UCB

| Country | Belgium |
| IPO Date | Aug 3, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10,117 |
| CEO | Jean-Christophe Tellier |
Contact Details
Allée de la Recherche, 60 Brussels,
BU 1070 Belgium
Stock Details
| Ticker Symbol | UCBJY |
| Exchange | OTC |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | 903480101 |
| ISIN Number | US9034801012 |
| SIC Code | n/a |
Recent News
- 1 month ago / seekingalpha.comUCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript
- 2 months ago / seekingalpha.comUCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript
- 2 months ago / seekingalpha.comUCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- 2 months ago / zacks.comUCB (UCBJY) Upgraded to Buy: Here's Why
- 3 months ago / zacks.comTrump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
- 4 months ago / seekingalpha.comUCB SA (UCBJY) Q2 2026 Earnings Call Transcript
Add to Watchlist
Select watchlists to add or remove UCBJY